MannKind Corp
MNKD3.895USD
+0.145+3.87%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.18BMarktkapitalisierung
39.31KGV TTM
mehr Informationen über MannKind Corp Unternehmen
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Unternehmensinformationen
BörsenkürzelMNKD
Name des UnternehmensMannKind Corp
IPO-datumJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Anzahl der mitarbeiter407
WertpapierartOrdinary Share
GeschäftsjahresendeJul 28
Addresse1 Casper Street
StadtDANBURY
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl06810
Telefon18186615000
Websitehttps://mannkindcorp.com/
BörsenkürzelMNKD
IPO-datumJul 28, 2004
CEODr. Michael E. Castagna, Pharm.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Christine Mundkur, J.D.
Ms. Christine Mundkur, J.D.
Independent Director
Independent Director
27.68K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
24.46K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product sales
47.79M
60.99%
Royalties
30.00M
38.29%
Services
558.00K
0.71%
Nach RegionUSD
Name
Umsatz
Anteil
United States
78.35M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product sales
47.79M
60.99%
Royalties
30.00M
38.29%
Services
558.00K
0.71%
Aktionärsstatistik
Aktualisiert: Fri, Aug 1
Aktualisiert: Fri, Aug 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.06%
The Vanguard Group, Inc.
5.68%
State Street Global Advisors (US)
3.12%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.56%
Other
78.71%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.06%
The Vanguard Group, Inc.
5.68%
State Street Global Advisors (US)
3.12%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.56%
Other
78.71%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
24.09%
Investment Advisor/Hedge Fund
18.22%
Hedge Fund
12.24%
Research Firm
3.11%
Individual Investor
1.75%
Bank and Trust
0.64%
Pension Fund
0.36%
Insurance Company
0.03%
Venture Capital
0.03%
Other
39.53%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
475
184.30M
60.64%
+2.96M
2025Q1
482
184.47M
60.73%
+2.52M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
2023Q1
412
147.80M
55.93%
-4.58M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
21.45M
7.06%
+246.00K
+1.16%
Mar 31, 2025
The Vanguard Group, Inc.
17.26M
5.68%
+1.26M
+7.90%
Mar 31, 2025
State Street Global Advisors (US)
9.47M
3.12%
-477.80K
-4.80%
Mar 31, 2025
Avoro Capital Advisors LLC
8.75M
2.88%
--
--
Mar 31, 2025
Nitorum Capital, L.P.
7.79M
2.56%
-961.61K
-10.99%
Mar 31, 2025
Two Sigma Investments, LP
7.11M
2.34%
+839.90K
+13.40%
Mar 31, 2025
Geode Capital Management, L.L.C.
6.79M
2.23%
+411.83K
+6.46%
Mar 31, 2025
UBS Financial Services, Inc.
6.50M
2.14%
+3.26M
+100.58%
Mar 31, 2025
Millennium Management LLC
5.82M
1.92%
+2.38M
+68.90%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.26M
1.4%
-215.90K
-4.82%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco Biotechnology & Genome ETF
2.36%
ALPS Medical Breakthroughs ETF
0.77%
VictoryShares Small Cap Free Cash Flow ETF
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.41%
Federated Hermes MDT Small Cap Core ETF
0.33%
SPDR S&P Biotech ETF
0.22%
Global X Aging Population ETF
0.21%
SPDR S&P Kensho New Economies Composite ETF
0.21%
First Trust Small Cap Growth AlphaDEX Fund
0.16%
Timothy Plan US Small Cap Core ETF
0.15%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil2.36%
ALPS Medical Breakthroughs ETF
Anteil0.77%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.45%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.41%
Federated Hermes MDT Small Cap Core ETF
Anteil0.33%
SPDR S&P Biotech ETF
Anteil0.22%
Global X Aging Population ETF
Anteil0.21%
SPDR S&P Kensho New Economies Composite ETF
Anteil0.21%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.16%
Timothy Plan US Small Cap Core ETF
Anteil0.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
